Journal of Cardiovascular Imaging

  • 제17권3호
  • /
  • Pages.86-95
  • /
  • 2009
  • /
  • 2586-7210(pISSN)
  • /
  • 2586-7296(eISSN)
한국심초음파학회 (Korean Society of Echocardiography)
권호 표지
DOI QR코드

DOI QR Code

THERAPEUTIC STRATEGIES FOR DIASTOLIC DYSFUNCTION: A CLINICAL PERSPECTIVE

  • Ha, Jong-Won (Division of Cardiology, Yonsei University College of Medicine) ;
  • Oh, Jae-K. (Division of Cardiovascular Diseases, Mayo Clinic)
  • 발행 : 2009.09.27
⟨ 이전 논문 다음 논문 ⟩

초록

Diastolic dysfunction, which is increasingly viewed as being influential in precipitating heart failure and determining prognosis, is often unrecognized and has therapeutic implications distinct from those that occur with systolic dysfunction. In this review, several therapeutic modalities including pharmacologic, nonpharmacologic, and surgical approaches for primary diastolic dysfunction and heart failure will be discussed.

키워드

참고문헌

  1. Mitsunami K, Inoue S, Maeda K, Endoh S, Takahashi M, Okada M, Sugihara H, Kinoshita M. Three-month effects of can-desartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998;12:469-74. https://doi.org/10.1023/A:1007754100351
  2. Angomachalelis N, Hourzamanis AI, Sideri S, Serasli E, Vamvalis C. Improvement of left ventricular diastolic dysfunction in hypertensive patients 1 month after ACE inhibition therapy: evaluation by ultrasonic automated boundary detection. Heart Vessels 1996;11:303-9. https://doi.org/10.1007/BF01747189
  3. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93. https://doi.org/10.1161/01.CIR.102.12.1388
  4. Lopez B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, Díez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286- 91. https://doi.org/10.1161/01.CIR.104.3.286
  5. Diez J, Querejeta R, López B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512-7. https://doi.org/10.1161/01.CIR.0000017264.66561.3D
  6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3
  7. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998;16:S23-9. https://doi.org/10.1097/00004872-199816010-00005
  8. Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999;33:1567- 72. https://doi.org/10.1016/S0735-1097(99)00048-0
  9. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial. Lancet 2003;362:777-81. https://doi.org/10.1016/S0140-6736(03)14285-7
  10. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67. https://doi.org/10.1056/NEJMoa0805450
  11. Dumesnil JG, Gaudreault G, Honos GN, Kingma JG Jr. Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension. Am J Cardiol 1991;68:515-9. https://doi.org/10.1016/0002-9149(91)90788-M
  12. Cheng CP, Igarashi Y, Little WC. Mechanism of augmented rate of left ventricular filling during exercise. Circ Res 1992;70:9-19. https://doi.org/10.1161/01.RES.70.1.9
  13. Gottdiener JS. Clinical trials of single-drug therapy for the cardiac effects of hypertension. Am J Hypertens 1999;12:S12-8. https://doi.org/10.1016/S0895-7061(98)00209-X
  14. Kass DA, Wolff MR, Ting CT, Liu CP, Chang MS, Lawrence W, Maughan WL. Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes. Ann Intern Med 1993;119:466-73. https://doi.org/10.7326/0003-4819-119-6-199309150-00004
  15. Nishimura RA, Schwartz RS, Holmes DR Jr, Tajik AJ. Failure of calcium channel blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 1993;21:182-8. https://doi.org/10.1016/0735-1097(93)90735-J
  16. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981-6. https://doi.org/10.1016/0002-9149(90)90937-V
  17. Betocchi S, Chiariello M. Effects of calcium antagonists on left ventricular structure and function. J Hypertens Suppl 1993;11:S33-7.
  18. Iliceto S. Left ventricular dysfunction: which role for calcium antagonists? Eur Heart J 1997;18 Suppl A:A87-91. https://doi.org/10.1093/eurheartj/18.suppl_A.87
  19. Ramirez Gil JF, Delcayre C, Robert V, Wassef M, Trouve P, Mougenot N, Charlemagen D, Lechat P. In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. J Cardiovasc Pharmacol 1998;32:927-34. https://doi.org/10.1097/00005344-199812000-00009
  20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. https://doi.org/10.1056/NEJM199909023411001
  21. Silvestre JS, Heymes C, Oubénaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99: 2694-701. https://doi.org/10.1161/01.CIR.99.20.2694
  22. Degre S, Detry JM, Unger P, Cosyns J, Brohet C, Kormoss N. Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol 1998;53:261-7.
  23. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994;89:2070-8. https://doi.org/10.1161/01.CIR.89.5.2070
  24. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 1999;41:514-23. https://doi.org/10.1016/S0008-6363(98)00314-9
  25. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation 1999;99:2396-401. https://doi.org/10.1161/01.CIR.99.18.2396
  26. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33. https://doi.org/10.1056/NEJM199702203360801
  27. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5. https://doi.org/10.1038/332411a0
  28. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78: 225-8. https://doi.org/10.1016/0021-9150(89)90227-X
  29. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75:1282-3. https://doi.org/10.1016/S0002-9149(99)80782-6
  30. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, Little WC. The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. Am J Physiol Heart Circ Psysiol 2001;280:H1853-60. https://doi.org/10.1152/ajpheart.2001.280.4.H1853
  31. Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-bromocGMP reduces the myofilament response to Ca2+ in intact cardiac myocyte. Circ Res 1994;74:970-8. https://doi.org/10.1161/01.RES.74.5.970
  32. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of the endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997;273:H2406-14.
  33. Clarkson PB, Wheeldon NM, MacFadyen RJ, Pringle SD, MacDonald TM. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996;93:2037-42. https://doi.org/10.1161/01.CIR.93.11.2037
  34. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, Kikuchi K. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376: 139-48. https://doi.org/10.1016/S0014-2999(99)00282-4
  35. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999;26:903-8. https://doi.org/10.1046/j.1440-1681.1999.03165.x
  36. Hernandez-Perera O, Pérez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000;87: 616-22. https://doi.org/10.1161/01.RES.87.7.616
  37. Park HJ, Galper JB. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci U S A 1999;96:11525-30. https://doi.org/10.1073/pnas.96.20.11525
  38. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500. https://doi.org/10.1161/01.RES.83.5.490
  39. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24. https://doi.org/10.1161/hc2801.094031
  40. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;83:345-52. https://doi.org/10.1161/01.RES.83.4.345
  41. Spurgeon HA, Steinbach MF, Lakatta EG. Chronic exercise prevents characteristic age-related changes in rat cardiac contraction. Am J Physiol 1983;244:H513-8.
  42. Starnes JW, Beyer RE, Edington DW. Myocardial adaptations to endurance exercise in aged rats. Am J Physiol 1983;245:H560-6.
  43. Gwathmey JK, Slawsky MT, Perreault CL, Briggs GM, Morgan JP, Wei JY. The effect of exercise conditioning on excitation-contraction coupling in aged rat. J Appl Physiol 1990;69:1366-71. https://doi.org/10.1152/jappl.1990.69.4.1366
  44. Tate CA, Taffet GE, Hudson EK, Blaylock SL, McBride RP, Michael LH. Enhanced calcium uptake of cardiac sarcoplasmic reticulum in exercise-trained old rats. Am J Physiol 1990;258:H431-5.
  45. Colan SD, Sanders SP, MacPherson D, Borow KM. Left ventricular diastolic function in elite athletes with physiologic cardiac hypertrophy. J Am Coll Cardiol 1985;6:545-9. https://doi.org/10.1016/S0735-1097(85)80111-X
  46. Douglas PA, O'Toole ML, Hiller WB, Reichek N. Left ventricular structure and function by echocardiography in ultraendurance athletes. Am J Cardiol 1986;58:805-9. https://doi.org/10.1016/0002-9149(86)90358-9
  47. Nixon JV, Wright AR, Porter TR, Roy V, Arrowood JA. Effects of exercise on left ventricular diastolic performance in trained athletes. Am J Cardiol 1991;68:945-9. https://doi.org/10.1016/0002-9149(91)90414-G
  48. Matsuda M, Sugishita Y, Koseki S, Ito I, Akatsuka T, Takamatsu K. Effect of exercise on left ventricular diastolic filling in athletes and nonathletes. J Appl Physiol 1983;55:323-8. https://doi.org/10.1152/jappl.1983.55.2.323
  49. Forman DE, Manning WJ, Hauser R, Gervino EV, Evans WJ, Wei JY. Enhanced left ventricular diastolic filling associated with long-term endurance training. J Gerontol 1992;47:M56-8. https://doi.org/10.1093/geronj/47.2.M56
  50. Takemoto KA, Bernstein L, Lopez JF, Marshak D, Rahimtoola SH, Chandraratna PA. Abnormalities of diastolic filling of the left ventricle associated with aging are less pronounced in exercise trained individuals. Am Heart J 1992;124:143-8. https://doi.org/10.1016/0002-8703(92)90932-L
  51. Douglas PS, O'Toole M. Aging and physical activity determine cardiac structure and function in the older athlete. J Appl Physiol 1992;72:1969- 73. https://doi.org/10.1152/jappl.1992.72.5.1969
  52. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 2002;20:1445-50. https://doi.org/10.1097/00004872-200207000-00033
  53. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001;344:17-22. https://doi.org/10.1056/NEJM200101043440103
  54. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-46. https://doi.org/10.1001/archinte.157.21.2413
  55. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102. https://doi.org/10.1016/S0895-7061(97)00224-0
  56. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998;16:747-52. https://doi.org/10.1097/00004872-199816060-00005
  57. Liu CP, Ting CT, Lawrence W, Maughan WL, Chang MS, Kass DA. Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants. Circulation 1993;88:1893-906. https://doi.org/10.1161/01.CIR.88.4.1893
  58. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-50. https://doi.org/10.1161/01.CIR.85.5.1743
  59. Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Phillips PJ, Callahan MJ, Schoen FJ, Grossman W, Morgan JP. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991;87:1023-31. https://doi.org/10.1172/JCI115061
  60. Levine HJ. Optimum heart rate of large failing hearts. Am J Cardiol 1988;61:633-6. https://doi.org/10.1016/0002-9149(88)90779-5
  61. Xiao HB, Brecker SJ, Gibson DG. Effects of abnormal activation on the time course of the left ventricular pressure pulse in dilated cardiomyopathy. Br Heart J 1992;68:403-7. https://doi.org/10.1136/hrt.68.10.403
  62. Littmann L, Symanski JD. Hemodynamic implications of left bundle branch block. J Electrocardiol 2000;33 suppl:115-21. https://doi.org/10.1054/jelc.2000.20330
  63. Saxon LA, Kerwin WF, Cahalan MK, Kalman JM, Olgin JE, Foster E, Schiller NB, Shinbane JS, Lesh MD, Merrick SH. Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/contraction sequence in patients with depressed ventricular function. J Cardiovasc Electrophysiol 1998;9:13-21. https://doi.org/10.1111/j.1540-8167.1998.tb00862.x
  64. Kerwin WF, Botvinick EH, O'Connell JW, Merrick SH, DeMarco T, Chatterjee K, Scheibly K, Saxon LA. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol 2000; 35:1221-7. https://doi.org/10.1016/S0735-1097(00)00555-6
  65. Nishimura RA, Hayes DL, Holmes DR Jr, Tajik AJ. Mechanism of hemodynamic improvement by dual-chamber pacing for severe left ventricular dysfunction: an acute Doppler and catheterization hemodynamic study. J Am Coll Cardiol 1995;25:281-8. https://doi.org/10.1016/0735-1097(94)00419-Q
  66. Panidis IP, Ross J, Munley B, Nestico P, Mintz GS. Diastolic mitral regurgitation in patients with atrioventricular conduction abnormalities: a common finding by Doppler echocardiography. J Am Coll Cardiol 1986;7:768-74. https://doi.org/10.1016/S0735-1097(86)80335-7
  67. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53. https://doi.org/10.1056/NEJMoa013168
  68. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985; 28:1-83. https://doi.org/10.1016/0033-0620(85)90024-6
  69. Betocchi S, Hess OM, Losi MA, Nonogi H, Krayenbuehl HP. Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation 1993;88:2206-14. https://doi.org/10.1161/01.CIR.88.5.2206
  70. Bonow RO, Vitale DF, Maron BJ, Bacharach SL, Frederick TM, Green MV. Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. J Am Coll Cardiol 1987;9:1108-16. https://doi.org/10.1016/S0735-1097(87)80315-7
  71. Severino S, Caso P, Galderisi M, De Simone L, Petrocelli A, de Divitiis O, Mininni N. Use of pulsed Doppler tissue imaging to assess regional left ventricular diastolic dysfunction in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:1394-98. https://doi.org/10.1016/S0002-9149(98)00648-1
  72. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4. https://doi.org/10.1016/S0140-6736(95)91267-3
  73. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-81. https://doi.org/10.1161/01.CIR.95.8.2075
  74. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH 3rd. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation1998; 98:1750-5. https://doi.org/10.1161/01.CIR.98.17.1750
  75. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-71. https://doi.org/10.1161/01.CIR.94.3.467
  76. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-8. https://doi.org/10.1016/S0735-1097(98)81739-7
  77. Weisfeldt ML. Function of cardiac muscle in aging rat. Adv Exp Med Biol 1975;61:95-118.
  78. Weisfeldt ML. Aging of the cardiovascular system. N Engl J Med 1980; 303:1172-4. https://doi.org/10.1056/NEJM198011133032009
  79. Weisfeldt M. Aging, changes in the cardiovascular system, and responses to stress. Am J Hypertens 1998;11:S41-5. https://doi.org/10.1016/S0895-7061(98)00009-0
  80. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev 1993;73:413-67.
  81. Taffet GE, Michael LA, Tate CA. Exercise training improves lusitropy by isoproterenol in papillary muscles from aged rats. J Appl Physiol 1996;81: 1488-94. https://doi.org/10.1152/jappl.1996.81.4.1488
  82. Takagishi Y, Rothery S, Issberner J, Levi A, Severs NJ. Spatial distribution of dihydropyridine receptors in the plasma membrane of guinea pig cardiac myocytes investigated by correlative confocal microscopy and label-fracture electron microscopy. J Electron Microsc (Tokyo) 1997; 46:165-70. https://doi.org/10.1093/oxfordjournals.jmicro.a023504
  83. Tate CA, Helgason T, Hyek MF, McBride RP, Chen M, Richardson MA, Taffet GE. SERCA2a and mitochondrial cytochrome oxidase expression are increased in hearts of exercise-trained old rats. Am J Physiol 1996;271:H68-72.
  84. Schmidt U, del Monte F, Miyamoto MI, Matsui T, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum $Ca^{2+}-$ ATPase. Circulation 2000;101:790-6. https://doi.org/10.1161/01.CIR.101.7.790
  85. Wahr PA, Michele DE, Metzger JM. Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc Natl Acad Sci 1999;96:11982-5. https://doi.org/10.1073/pnas.96.21.11982
  86. Celio MR, Heizmann CW. Calcium-binding protein parvalbumin is associated with fast contracting muscle fibres. Nature 1982;297:504-6. https://doi.org/10.1038/297504a0
  87. Hou TT, Johnson JD, Rall JA. Parvalbumin content and $Ca^{2+}$ and $Mg^{2+}$ dissociation rates correlated with changes in relaxation rate of frog muscle fibres. J Physiol 1991;441:285-304. https://doi.org/10.1113/jphysiol.1991.sp018752
  88. Rall JA. Role of parvalbumin in skeletal muscle contraction. News in Physiological Science 1996;11:249-55.
  89. Szatkowski ML, Westfall MV, Gomez CA, Wahr PA, Michele DE, DelloRusso C, Turner II, Hong KE, Albayya FP, Metzger JM. In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. J Clin Invest 2001;107:191-8. https://doi.org/10.1172/JCI9862
  90. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventriclar diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 1997;10:246-70. https://doi.org/10.1016/S0894-7317(97)70062-2
  91. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997;30:8-18. https://doi.org/10.1016/S0735-1097(97)00144-7

피인용 문헌

  1. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled tria vol.17, pp.1, 2009, https://doi.org/10.1186/s13063-016-1656-y
  2. High‐risk catheter ablation of refractory atrial fibrillation using Impella CP in a patient with cardiogenic shock vol.43, pp.10, 2009, https://doi.org/10.1111/pace.14037
  3. MK2‐Deficient Mice Are Bradycardic and Display Delayed Hypertrophic Remodeling in Response to a Chronic Increase in Afterload vol.10, pp.4, 2021, https://doi.org/10.1161/jaha.120.017791
  4. Diastolic Dysfunction Is a Predictor of Poor Survival in Patients with Decompensated Cirrhosis vol.2021, pp.None, 2009, https://doi.org/10.1155/2021/5592376
  5. Personalized intervention cardiology with transcatheter aortic valve replacement made possible with a non-invasive monitoring and diagnostic framework vol.11, pp.1, 2009, https://doi.org/10.1038/s41598-021-85500-2